Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

You may be eligible if

• The study is now in the phase II expansion phase.
• The target tumor is limited to neuroblastoma and the diagnosis should be histologically verified.
• Patients must have refractory or recurrent malignancy; patient's current disease state must be one for which no known curative therapy is available;
• Patients should not receive any other experimental or phase 1 therapy within 3 weeks prior to study enrollment and monoclonal antibody therapy within 6 weeks
• To be eligible for phase I study patients should have primary refractory or relapsed disease as evidenced by:
• * Local tumor recurrence measurable on CT or magnetic resonance imaging (MRI) scans with or without metastatic lesions
• * Refractory bone marrow involvement in patients with NB
• * NB with MIBG-positive skeletal lesions
• The presence of radiographically measurable disease immediately prior to start of Phase I immunotherapy is not an eligibility requirement in the following situations:
• * In patients with NB who have documented bone marrow (BM) involvement;
• * In patients with NB who have MIBG-positive bony lesion(s);
• An additional eligibility requirement for phase II study includes the presence of radiographically measurable disease with the exception of MIBG-positive NB or NB with bone marrow involvement:
• Patients must have a Lansky or Karnofsky performance status score of \>= 70
• Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
• * Myelosuppressive chemotherapy: must not have received within 3 weeks of starting immunotherapy (IT)
• * Hematopoietic growth factors: at least 7 days since the last dose of growth factor therapy
• * Immunotherapy: at least 6 weeks must have elapsed since prior therapy that includes a monoclonal antibody
• Normal organ function
• All patients or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines
• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met